Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib plus R-CHOP versus placebo plus R-CHOP in previously untreated non-germinal center diffuse large B-cell lymphoma
2023-509358-72-00Phase 3Authorised
- Sponsor
- Acerta Pharma
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial of acalabrutinib in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Acerta Pharma. Primary endpoint: Progression-free survival. Planned start Nov 2020; status: authorised.
02
Drugs
acalabrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2023-509358-72-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509358-72-00.